Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.36 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.31 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22867141 | 0.92 | NLRP3 (0.41) | NLRP3CYP46A1EGLN1PLCG1 | |
| SCHEMBL22867010 | 0.72 | ACVR2A (0.39) | NLRP3PLCG1CDK5CDK5R1 | |
| SCHEMBL25281510 | 0.71 | CNR1 (0.43) | NLRP3CYP46A1EGLN1SLC6A4SLC6A3 | |
| SCHEMBL22866621 | 0.71 | CYP46A1 (0.40) | NLRP3CYP46A1EGLN1SLC6A4SLC6A3 | |
| SCHEMBL22867183 | 0.70 | NLRP3 (0.37) | NLRP3GABRA1 | |
| SCHEMBL29173821 | 0.65 | KDM4E (0.55) | ALDH1A1ACACBHTT | |
| SCHEMBL13714155 | 0.65 | SLC6A4 (0.41) | ALDH1A1SLC6A4SLC6A3HTTAR | |
| SCHEMBL20744375 | 0.64 | NLRP3 (0.41) | NLRP3ALDH1A1ACACB | |
| SCHEMBL30684077 | 0.64 | NLRP3 (0.41) | NLRP3ALDH1A1ACACB | |
| SCHEMBL17429767 | 0.64 | EGLN1 (0.37) | EGLN1ALDH1A1ACACBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885CYP46A1 352/4885EGLN1 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.